-
SAUDI
North America
South America
Europe
Nano™ 2nd Gen
embecta helps your patients with diabetes correctly inject their insulin with innovative pen needle technology.
- Overview
Despite your best efforts to educate patients around proper injection technique, it has been shown that most patients inject their insulin using a wide range of techniques and forces, resulting in injection technique errors. In a recent observational study, all patients surveyed were making at least 1 injection technique error, with 76% of them applying too much force against the skin while injecting, which can impact the proper subcutaneous delivery and absorption of insulin.1*
Contoured Base
NanoTM 2nd Gen 4mm pen needle has a unique contoured needle base that distributes forces across the skin surface, compensating for the force used to inject and allowing for less bruising and reduced risk of intramuscular injection.2,3
Confidence
The Nano™ 2nd Gen 4mm x 32 G Pen Needle has ultra-thin wall technology, the highest inner diameter ISO standard for its category, and studies have shown that the increased flow of insulin results in greater ease of use and increased confidence that the complete dose has been delivered.4,5‡
Comfort
In a study, the NanoTM 2nd Gen 4mm needle with 5-bevel tip provided more comfortable and less painful injections.6§
Ease of Use
Nano™ 2nd Gen Pen Needles have an ergonomic design proven to make them easier to use from attachment through disposal.6¶
Single Use
Recommend the use of a new pen needle every time your patients inject. Pen needles are recommended to be used only once and are no longer sterile after that.8
Compatibility
NanoTM 2nd Gen 4mm Pen Needles are compatible with widely used pen injection devices, so even if your patient's treatment regimen changes, you wonʼt have to change your choice of pen needle for them.7
*230 patients with diabetes surveyed as part of a cross-sectional observational behavioral study in Canada.
‡ 198 patients with diabetes were included in this prospective, multicenter, randomized, open-label, 2-period, crossover study to evaluate differences in perceived thumb force and in confidence that the full dose of insulin was delivered, between the participants’ usual pen needle (PN) and the corresponding extra-thin wall (XTW) pen needle. Significant differences favoring XTW pen needles were seen for perceived thumb force and confidence that the full dose was delivered by 28.4mm (95% CI, 23.7-33.2), and 24.4mm (95% CI, 19.7-29.1), respectively; (all, P<0.001). Ultra-thin wall introduced as an ISO standard for inner wall diameter in 2016.
§ Patients were aware of the pen needle they were using.
¶ 226 patients with diabetes on insulin treatment were studied with a 150 mm visual analog scale (mean scores of >0 mm; clinically significant difference of ≥5 mm). Nano 2nd Gen demonstrated superiority vs. all comparator groups combined for overall ease of use (P <0.05)(Mean 19.9 mm, 95% CI, +13.8 to +25.9 mm).
1. Bari B, Corbeil MA, Farooqui H, et al. Insulin injection practices in a population of Canadians with diabetes: an observational study. Diabetes Ther. 2020;11(11):2595-2609.
2. Rini C, Roberts BC, Morel D, et al. Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol. 2019;13(3):533-545.
3. Klonoff DC, Berard L, Franco DR, et al. Advance Insulin Injection Technique and Education with FITTER Forward Expert Recommendations. Mayo Clin Proc. 2025; 100(4):682-699.
4. Aronson R, Gibney MA, Oza K, et al. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35(7):923-933.
5. Stainless steel needle tubing for the manufacture of medical devices —requirements and test methods. ISO 9626. 2016.
6. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a modified needle tip geometry on penetration force as well as acceptability, preference, and perceived pain in subjects with diabetes. J Diabetes Sci Technol. 2012;6(2):328-335.
7. Pen Needle Compatibility Status Summary with Diabetes Care & Non-Diabetes Drug Delivery Devices - Document Number: 149OTH-0004-20 Rev Y – 2025-11-18.
8. Frid AH, et al. New Insulin Delivery Recommendations. Mayo Clinic Proceedings. 2016;91(9):1231–1255.